Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects

References

• Center for Disease Control. HIV/AIDS Surveillance Report 2010, Supplemental Report, Estimated HIV incidence in the United States, 2007-2010. 2010; (Vol. 17, Number 4). http://www.cdc.gov/hiv/pdf/statistics_hssr_vol_17_no_4.pdf. Accessed May 30, 2014
   Google Scholar
• Centers for Disease Control and Prevention. HIV Surveillance Report, 2011; 2013; vol. 23. Rates of diagnoses of HIV infection among adults and adolescents, by area of residence, 2011 - United States and 6 dependent areas. Published February 2013. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Accessed May 30, 2014.
   Google Scholar
• Hankins, C.. Overview of the current state of the epidemic. Current HIV/AIDS reports 2013; 10, 113-123.
   PubMedGoogle Scholar
• O'Connell RJ, Kim JH, Corey L, Michael NL. Human immunodeficiency virus vaccine trials. Cold Spring Harb Perspect Med 2 2012; a007351
   PubMedGoogle Scholar
• Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF, rgp, H.I.V. Vaccine Study Group. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 2005; 191, 654-65; PMID:15688278; http://dx.doi.org/10.1086/428404
   PubMed Web of Science ®Google Scholar
• Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, Hu D, Tappero JW, Choopanya K, Bangkok Vaccine Evaluation, G.. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194, 1661-71; PMID:17109337; http://dx.doi.org/10.1086/508748
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009; 361, 2209-20; PMID:19843557; http://dx.doi.org/10.1056/NEJMoa0908492
   PubMed Web of Science ®Google Scholar
• Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, Evans DT, Montefiori DC, Karnasuta C, Sutthent R, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 2012; 366, 1275-86; PMID:22475592; http://dx.doi.org/10.1056/NEJMoa1113425
   PubMed Web of Science ®Google Scholar
• de Souza MS, Ratto-Kim S, Chuenarom W, Schuetz A, Chantakulkij S, Nuntapinit B, Valencia-Micolta A, Thelian D, Nitayaphan S, Pitisuttithum P, et al. The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J Immunol 2012; 188, 5166-76; http://dx.doi.org/10.4049/jimmunol.1102756
   PubMed Web of Science ®Google Scholar
• Cao J, McNevin J, Holte S, Fink L, Corey L, McElrath MJ. Comprehensive analysis of human immunodeficiency virus type 1 (HIV-1)-specific gamma interferon-secreting CD8+ T cells in primary HIV-1 infection. J Virol 2003; 77, 6867-78; PMID:12768006; http://dx.doi.org/10.1128/JVI.77.12.6867-6878.2003
   PubMedGoogle Scholar
• Kaufmann DE, Bailey PM, Sidney J, Wagner B, Norris PJ, Johnston MN, Cosimi LA, Addo MM, Lichterfeld M, Altfeld M, et al. Comprehensive analysis of human immunodeficiency virus type 1-specific CD4 responses reveals marked immunodominance of gag and nef and the presence of broadly recognized peptides. J Virol 2004; 78, 4463-77; PMID:15078927; http://dx.doi.org/10.1128/JVI.78.9.4463-4477.2004
   PubMed Web of Science ®Google Scholar
• Pontesilli O, Klein MR, Kerkhof-Garde SR, Pakker NG, de Wolf F, Schuitemaker H, Miedema F. Kinetics of immune functions and virus replication during HIV-1 infection. Immunol Lett 1997; 57, 125-30; PMID:9232438; http://dx.doi.org/10.1016/S0165-2478(97)00047-3
   PubMedGoogle Scholar
• Sanou MP, De Groot AS, Murphey-Corb M, Levy JA, Yamamoto JK. HIV-1 Vaccine Trials: Evolving Concepts and Designs. open AIDS J 2012; 6, 274-88; PMID:23289052; http://dx.doi.org/10.2174/1874613601206010274
   PubMedGoogle Scholar
• Uhl EW, Heaton-Jones TG, Pu R, Yamamoto JK. FIV vaccine development and its importance to veterinary and human medicine: a review FIV vaccine 2002 update and review. Vet Immunol Immunopathol 2002; 90, 113-32; PMID:12459160; http://dx.doi.org/10.1016/S0165-2427(02)00227-1
   PubMed Web of Science ®Google Scholar
• Elder JH, Lin YC, Fink E, Grant CK. Feline immunodeficiency virus (FIV) as a model for study of lentivirus infections: parallels with HIV. Curr HIV Res 2010; 8, 73-80; PMID:20210782; http://dx.doi.org/10.2174/157016210790416389
   PubMed Web of Science ®Google Scholar
• Kenyon JC, Lever AM. The molecular biology of feline immunodeficiency virus (FIV). Viruses 2011; 3, 2192-213; PMID:22163340; http://dx.doi.org/10.3390/v3112192
   PubMedGoogle Scholar
• Coleman JK, Pu R, Martin MM, Noon-Song EN, Zwijnenberg R, Yamamoto JK. Feline immunodeficiency virus (FIV) vaccine efficacy and FIV neutralizing antibodies. Vaccine 2014; 32, 746-54; PMID:23800540; http://dx.doi.org/10.1016/j.vaccine.2013.05.024
   PubMedGoogle Scholar
• Uhl EW, Martin M, Coleman JK, Yamamoto JK. Advances in FIV vaccine technology. Vet Immunol Immunopathol 2008; 123, 65-80; PMID:18295907; http://dx.doi.org/10.1016/j.vetimm.2008.01.030
   PubMedGoogle Scholar
• Coleman JK, Pu R, Martin M, Sato E, Yamamoto JK. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection. Aids 2005; 19, 1457-66; PMID:16135898; http://dx.doi.org/10.1097/01.aids.0000183627.81922.be
   PubMedGoogle Scholar
• Pontesilli O, Carotenuto P, Kerkhof-Garde SR, Roos MT, Keet IP, Coutinho RA, Goudsmit J, Miedema F. Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection. AIDS Res Hum Retroviruses 1999; 15, 973-81; PMID:10445809; http://dx.doi.org/10.1089/088922299310485
   PubMed Web of Science ®Google Scholar
• Rosenberg ES, Billingsley JM, Caliendo AM, Boswell SL, Sax PE, Kalams SA, Walker BD. Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 1997; 278, 1447-50; PMID:9367954; http://dx.doi.org/10.1126/science.278.5342.1447
   PubMed Web of Science ®Google Scholar
• Gillespie GM, Kaul R, Dong T, Yang HB, Rostron T, Bwayo JJ, Kiama P, Peto T, Plummer FA, McMichael AJ, et al. Cross-reactive cytotoxic T lymphocytes against a HIV-1 p24 epitope in slow progressors with B*57. Aids 2002; 16, 961-72; PMID:11953462; http://dx.doi.org/10.1097/00002030-200205030-00002
   PubMed Web of Science ®Google Scholar
• Zhang Y, Huber M, Euler-Konig I, Sussmuth R, Jung G, Jassoy C. Analysis of the proliferative responses to peptides in individuals with vigorous Gag protein-specific proliferation. Immunol Lett 2001; 79, 93-6; PMID:11595294; http://dx.doi.org/10.1016/S0165-2478(01)00270-X
   PubMedGoogle Scholar
• Mothe B, Llano A, Ibarrondo J, Zamarreno J, Schiaulini M, Miranda C, Ruiz-Riol M, Berger CT, Herrero MJ, Palou E, et al. CTL responses of high functional avidity and broad variant cross-reactivity are associated with HIV control. PloS one 2012; 7, e29717; PMID:22238642; http://dx.doi.org/10.1371/journal.pone.0029717
   PubMed Web of Science ®Google Scholar
• Shmelkov E, Nadas A, Cardozo T. Could vaccination with AIDSVAX immunogens have resulted in antibody-dependent enhancement of HIV infection in human subjects? Hum Vacc Immunother. 2014; Ten:10, 3013-16
   PubMed Web of Science ®Google Scholar
• Hosie MJ, Osborne R, Reid G, Neil JC, Jarrett O. Enhancement after feline immunodeficiency virus vaccination. Vet Immunol Immunopathol. 1992; 35:191-7; PMID:1337397; http://dx.doi.org/10.1016/0165-2427(92)90131-9
   PubMed Web of Science ®Google Scholar
• Flynn JN, Cannon CA, Neil JC, Jarrett O. Vaccination with a Feline Immunodeficiency Virus Multiepitopic Peptide Induces Cell-Mediated and Humoral Immune Responses in Cats, but Does Not Confer Protection. J Virol. 1997; 71:10 7586-92. J Virol. 1997 Dec; 71(12):9640-9; PMID:9371628
   PubMedGoogle Scholar
• Richardson J1, Moraillon A, Baud S, Cuisinier AM, Sonigo P, Pancino G. Enhancement of feline immunodeficiency virus (FIV) infection after DNA vaccination with the FIV envelope. J Virol 1997; Dec;71(12):9640-9; PMID:9371628
   PubMedGoogle Scholar
• Siebelink KH1, Tijhaar E, Huisman RC, Huisman W, de Ronde A, Darby IH, Francis MJ, Rimmelzwaan GF, Osterhaus AD. Enhancement of feline immunodeficiency virus infection after immunization with envelope glycoprotein subunit vaccines. J Virol 1995; 1995 Jun;69(6):3704-11
   PubMed Web of Science ®Google Scholar
• Spina CA, Prince HE, Richman DD. Preferential replication of HIV-1 in the CD45RO memory cell subset of primary CD4 lymphocytes in vitro. J Clin Investig 1997; 99, 1774-85; PMID:9120023; http://dx.doi.org/10.1172/JCI119342
   PubMedGoogle Scholar
• Stevenson M, Stanwick TL, Dempsey MP, Lamonica CA. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J 1990; 9, 1551-60; PMID:2184033
   PubMed Web of Science ®Google Scholar
• Yamamoto JK, Barre-Sinoussi F, Bolton V, Pedersen NC, Gardner MB. Human alpha- and beta-interferon but not gamma- suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J Interferon Res 1986; 6, 143-52. -152; PMID:2425014; http://dx.doi.org/10.1089/jir.1986.6.143
   PubMedGoogle Scholar
• Roff SR, Noon-Song EN, Yamamoto JK. The Significance of Interferon-gamma in HIV-1 Pathogenesis, Therapy, and Prophylaxis. Front Immunol 2014; 4, 498; PMID:24454311; http://dx.doi.org/10.3389/fimmu.2013.00498
   PubMed Web of Science ®Google Scholar
• Marsh SG, Parham P, Barber LD 2000. The HLA Class I and Class II Loci. In Marsh S.G., Parham P., Barber L.D. (eds), The HLA Facts Book. London: Academy Press; p. 93-272
   Google Scholar
• Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, Reddy S, de Pierres C, Mncube Z, Mkhwanazi N, et al. CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13, 46-53; PMID:17173051; http://dx.doi.org/10.1038/nm1520
   PubMed Web of Science ®Google Scholar
• Leslie A, Matthews PC, Listgarten J, Carlson JM, Kadie C, Ndung'u T, Brander C, Coovadia H, Walker BD, Heckerman D, et al. Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. J Virol 2010; 84, 9879-88; PMID:20660184; http://dx.doi.org/10.1128/JVI.00320-10
   PubMedGoogle Scholar
• Carlson JM, Listgarten J, Pfeifer N, Tan V, Kadie C, Walker BD, Ndung'u T, Shapiro R, Frater J, Brumme ZL, et al. Widespread impact of HLA restriction on immune control and escape pathways of HIV-1. J Virol 2012; 86, 5230-43; PMID:22379086; http://dx.doi.org/10.1128/JVI.06728-11
   PubMedGoogle Scholar
• Tang J, Cormier E, Gilmour J, Price MA, Prentice HA, Song W, Kamali A, Karita E, Lakhi S, Sanders EJ, et al. Human leukocyte antigen variants B*44 and B*57 are consistently favorable during two distinct phases of primary HIV-1 infection in sub-Saharan Africans with several viral subtypes. J Virol 2011; 85, 8894-902; PMID:21715491; http://dx.doi.org/10.1128/JVI.00439-11
   PubMedGoogle Scholar
• Zhang X, Huang X, Xia W, Li W, Zhang T, Wu H, Xu X, Yan H. HLA-B*44 is associated with a lower viral set point and slow CD4 decline in a cohort of Chinese homosexual men acutely infected with HIV-1. Clin Vaccine Immunol 2013; 20, 1048-54; PMID:23677320; http://dx.doi.org/10.1128/CVI.00015-13
   PubMedGoogle Scholar
• Goulder PJ, Walker BD. HIV and HLA class I: an evolving relationship. Immunity 2012; 37, 426-40; PMID:22999948; http://dx.doi.org/10.1016/j.immuni.2012.09.005
   PubMed Web of Science ®Google Scholar
• MacDonald KS, Embree JE, Nagelkerke NJ, Castillo J, Ramhadin S, Njenga S, Oyug J, Ndinya-Achola J, Barber BH, Bwayo JJ, et al. The HLA A2/6802 supertype is associated with reduced risk of perinatal human immunodeficiency virus type 1 transmission. J Infect Dis 2001; 183, 503-6; PMID:11133384; http://dx.doi.org/10.1086/318092
   PubMedGoogle Scholar
• MacDonald KS, Matukas L, Embree JE, Fowke K, Kimani J, Nagelkerke NJ, Oyugi J, Kiama P, Kaul R, Luscher MA, et al. Human leucocyte antigen supertypes and immune susceptibility to HIV-1, implications for vaccine design. Immunol Lett 2001; 79, 151-7; PMID:11595302; http://dx.doi.org/10.1016/S0165-2478(01)00277-2
   PubMed Web of Science ®Google Scholar
• Liu C, Carrington M, Kaslow RA, Gao X, Rinaldo CR, Jacobson LP, Margolick JB, Phair J, O'Brien SJ, Detels R. Association of polymorphisms in human leukocyte antigen class I and transporter associated with antigen processing genes with resistance to human immunodeficiency virus type 1 infection. J Infect Dis 2003; 187, 1404-10; PMID:12717621; http://dx.doi.org/10.1086/374394
   PubMedGoogle Scholar
• Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH, et al. Analysis of HLA A*02 Association with Vaccine Efficacy in the RV144 HIV-1 Vaccine Trial. J Virol 2014; 88, 8242-55; PMID:24829343; http://dx.doi.org/10.1128/JVI.01164-14
   PubMed Web of Science ®Google Scholar
• Gonzalez-Galarza FF, Christmas S, Middleton D, Jones AR. Allele frequency net: a database and online repository for immune gene frequencies in worldwide populations. Nucleic Acid Res 2011; 39, D913-D919; http://dx.doi.org/10.1093/nar/gkq1128
   Web of Science ®Google Scholar
• Allele Frequency Net Database, http://www.allelefrequencies.net/ Accessed October 2, 2014
   Google Scholar
• Jones RB, Garrison KE, Mujib S, Mihajlovic V, Aidarus N, Hunter DV, Martin E, John VM, Zhan W, Faruk NF, et al. HERV-K-specific T cells eliminate diverse HIV-1/2 and SIV primary isolates. J Clin Invest 2012; 122:4473-4489; PMID:23143309; http://dx.doi.org/10.1172/JCI64560
   PubMed Web of Science ®Google Scholar
• Sanou MP, Roff SR, Mennella A, Sleasman JW, Rathore MH, Yamamoto JK, Levy JA. Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects. J Virol 2013; 87, 10004-15; PMID:23824804; http://dx.doi.org/10.1128/JVI.00359-13
   PubMedGoogle Scholar
• Almeida JR, Price DA, Papagno L, Arkoub ZA, Sauce D, Bornstein E, Asher TE, Samri A, Schnuriger A, Theodorou I, et al. Superior control of HIV-1 replication by CD8+ T cells is reflected by their avidity, polyfunctionality, and clonal turnover. J Exp Med 2007; 204, 2473-85; PMID:17893201; http://dx.doi.org/10.1084/jem.20070784
   PubMed Web of Science ®Google Scholar
• Sidney J, Peters B, Frahm N, Brander C, Setter A. HLA class I supertypes: a revised and updated classification. BMC Immunol 2008; 9:1; PMID:18211710; http://dx.doi.org/10.1186/1471-2172-9-1
   PubMed Web of Science ®Google Scholar
• Abbott JR, Pu R, Coleman JK, Yamamoto JK. Utilization of feline ELISPOT for mapping vaccine epitopes. Methods in Molecular Biology 2012; 792, 47-63; PMID:21956500; http://dx.doi.org/10.1007/978-1-61779-325-7_4
   PubMedGoogle Scholar
• Lichterfeld M, Kaufmann DE, Yu XG, Mui SK, Addo MM, Johnston MN, Cohen D, Robbins GK, Pae E, Alter G, et al. Loss of HIV-1-specific CD8+ T cell proliferation after acute HIV-1 infection and restoration by vaccine-induced HIV-1-specific CD4+ T cells. J Exp Med 2004; 200, 701-12; PMID:15381726; http://dx.doi.org/10.1084/jem.20041270
   PubMed Web of Science ®Google Scholar
• Horton H, Thomas EP, Stucky JA, Frank I, Moodie Z, Huang Y, Chiu YL, McElrath MJ, De Rosa SC. Optimization and validation of an 8-color intracellular cytokine staining (ICS) assay to quantify antigen-specific T cells induced by vaccination. J Immunol Methods 2007; 323, 39-54; PMID:17451739; http://dx.doi.org/10.1016/j.jim.2007.03.002
   PubMed Web of Science ®Google Scholar
• Pattacini L, Mize GJ, Graham JB, Fluharty TR, Graham TM, Lingnau K, Wizel B, Perdiguero B, Esteban M, Pantaleo G, et al. A novel HIV vaccine adjuvanted by IC31 induces robust and persistent humoral and cellular immunity. PloS one 2012; 7, e42163; PMID:22848738; http://dx.doi.org/10.1371/journal.pone.0042163
   PubMedGoogle Scholar